Ardelyx Misses Q1 EPS and Revenue but Stock Edges Higher on Guidance Reaffirmation
Ardelyx (NASDAQ: ARDX) posted a Q1 2026 loss of $0.15 per share and revenue of $93.4 million, both falling short of consensus estimates. Despite the miss, the stock nudged up 0.32% in after‑hours trading to $6.35 as investors cheered the company’s reaffirmed full‑year guidance and strong product‑level growth.
Earnings Snapshot
- GAAP EPS: ‑$0.15 vs. consensus ‑$0.14 (miss by $0.01)
- Revenue: $93.4 million vs. $96.4 million expected (miss by $3.0 million)
- YoY Revenue Growth: 38% driven by IBSRELA (tenapanor) and XPHOZAH sales.
- Cash Position: $238.1 million as of March 31, 2026.
Why the Stock Tick‑Up?
The modest after‑hours gain reflects a market focus on the guidance reaffirmation rather than the top‑line miss.
- Ardelyx reiterated its 2026 revenue targets: IBSRELA $410‑$430 million and XPHOZAH $110‑$120 million.
- CEO Mike Raab highlighted that IBSRELA is on a “blockbuster trajectory” with a goal of $1 billion annual sales by 2029, and that the company now has the cash flexibility to fund multiple Phase 3 trials, including the ACCEL study for chronic idiopathic constipation (CIC).
- The company also announced the start of dosing for the ACCEL trial in January and expects enrollment to finish by year‑end, with topline data slated for H2 2027.
- A new multi‑year partnership with the LPGA and recent executive hires were cited as catalysts for brand visibility and operational execution.
Conference Call Highlights
- Commercial Execution: 58% YoY growth for IBSRELA (to $70.1 million) and a 23% increase in XPHOZAH prescriptions, driven by new prescriber outreach and improved pull‑through.
- R&D Momentum: $20.2 million spent on R&D, up from $14.9 million a year ago, reflecting the ACCEL trial spend.
- SG&A Expansion: $102.3 million, up 23% YoY, supporting field‑force growth and marketing initiatives.
- Cash Management: Refinancing with SLR Investment Corp improved debt terms, preserving liquidity for pipeline advancement.
Analyst Reaction
- Wedbush reiterated an Outperform rating with a $19 price target, noting the “strong commercial momentum and clear path to a $1 billion IBSRELA franchise.”
- Zacks upgraded Ardelyx to a #2 (Buy) rank, citing the reaffirmed guidance and the upcoming Phase 3 data as upside catalysts.
- MarketBeat analysts called the earnings “mixed” but emphasized that the guidance beat the market’s revenue expectations for the full year, supporting a modest post‑earnings rally.
Stock Reaction
- After the earnings release, ARDX traded up 0.32% in after‑hours, closing at $6.35 versus the prior close of $6.33.
- The move, while modest, reflects investor confidence that the company’s cash runway and pipeline milestones outweigh the short‑term revenue miss.
Outlook
Ardelyx’s trajectory hinges on delivering Phase 3 data for the ACCEL trial and sustaining IBSRELA’s prescription growth. If the company meets its 2026 revenue guidance, the stock could see further upside, especially as analysts continue to raise price targets ahead of the anticipated $1 billion milestone.
---
All figures are from Ardelyx’s Q1 2026 Form 8‑K filing and corroborated by market‑wide analyst commentary.
Key Takeaways
- Ardelyx missed Q1 EPS (-$0.15) and revenue ($93.4 M) but reaffirmed 2026 guidance, keeping investors upbeat.
- IBSRELA revenue surged 58% YoY to $70.1 M, positioning the drug for a potential $1 B annual franchise by 2029.
- Analysts (Wedbush, Zacks) maintained bullish stances, with Wedbush keeping an Outperform rating and a $19 price target.
- After‑hours stock rose 0.32% to $6.35, reflecting confidence in cash strength ($238.1 M) and upcoming Phase 3 ACCEL trial data.
- Key upcoming catalyst: topline results from the ACCEL Phase 3 trial for chronic idiopathic constipation expected in H2 2027.